Biomarkers Shine, Results Disappoint: Novo's Attempt at Alzheimer's Falls Short
- Novo Nordisk's Alzheimer's trials for semaglutide failed to meet primary endpoints, causing a 9% premarket stock drop to a multi-year low. - The $3.8B trial showed no disease progression slowing despite biomarker improvements, with UBS estimating only 10% success probability beforehand. - Market ripple effects included Eli Lilly's 0.5% decline and Biogen's 2.7% rise, highlighting GLP-1 drug competition in neurodegenerative therapies. - This setback compounds Novo's challenges: 50% YTD stock decline, obes
Novo Nordisk (NVO) shares dropped to their lowest point in years on Monday after the Danish pharmaceutical company revealed that its phase 3 studies of semaglutide for Alzheimer's disease did not achieve their main goal. The EVOKE and EVOKE+ studies, which included 3,808 participants in the early stages of Alzheimer's,
This development is a significant setback for
The market’s response was not limited to
Novo Nordisk’s recent troubles are part of a broader set of challenges. The company, whose shares have dropped more than 50% so far this year, recently
The company intends to share headline results from the studies at the Clinical Trials on Alzheimer's Disease (CTAD) conference in December 2025, with comprehensive data expected at the AD/PD 2026 event
---
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Solana price recovery cut short as Pump.fun’s $436M USDC outflow spooks investors

5 reasons for Bitcoin’s selloff according to Deutsche Bank

Zcash price holds key level: can bulls break to $1000 next?

Pi Network price forecast: GCV and the Map of Pi 2.0 drive the narrative
